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Abstract
Transport And Golgi Organization protein 2 (TANGO2) deficiency has recently
been identified as a rare metabolic disorder with a distinct clinical and biochemical
phenotype of recurrent metabolic crises, hypoglycemia, lactic acidosis, rhabdomy-
olysis, arrhythmias, and encephalopathy with cognitive decline. We report nine
subjects from seven independent families, and we studied muscle histology, respi-
ratory chain enzyme activities in skeletal muscle and proteomic signature of fibro-
blasts. All nine subjects carried autosomal recessive TANGO2 mutations. Two
carried the reported deletion of exons 3 to 9, one homozygous, one heterozygous
with a 22q11.21 microdeletion inherited in trans. The other subjects carried three
novel homozygous (c.262C>T/p.Arg88*; c.220A>C/p.Thr74Pro; c.380+1G>A),
and two further novel heterozygous (c.6_9del/p.Phe6del); c.11-13delTCT/p.
Phe5del mutations. Immunoblot analysis detected a significant decrease of
TANGO2 protein. Muscle histology showed mild variation of fiber diameter, no
ragged-red/cytochrome c oxidase-negative fibers and a defect of multiple respira-
tory chain enzymes and coenzyme Q10 (CoQ10) in two cases, suggesting a possible
secondary defect of oxidative phosphorylation. Proteomic analysis in fibroblasts
revealed significant changes in components of the mitochondrial fatty acid oxida-
tion, plasma membrane, endoplasmic reticulum-Golgi network and secretory path-
ways. Clinical presentation of TANGO2 mutations is homogeneous and clinically
recognizable. The hemizygous mutations in two patients suggest that some muta-
tions leading to allele loss are difficult to detect. A combined defect of the respira-
tory chain enzymes and CoQ10 with altered levels of several membrane proteins
provides molecular insights into the underlying pathophysiology and may guide
rational new therapeutic interventions.
KEYWORD S
fatty acid metabolism, metabolic encephalomyopathy, mitochondrial dysfunction, proteomic analysis,
rhabdomyolysis, TANGO2
1 | BACKGROUND
The family of TANGO proteins plays a crucial role in the inter-
action of the Golgi apparatus and the endoplasmic reticulum
(ER). Bi-allelic TANGO2 (NM_152906.5) mutations have been
identified as a cause of a pediatric disease with multi-organ
involvement.1,2 TANGO2 was first described in a genome-wide
RNA-mediated interference screen in Drosophila.3 TANGO2 is
localized to the Golgi and the cytoplasm. Its depletion leads to
the fusion of Golgi membranes with the ER.4 Consequently,
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increased ER stress was postulated to be a contributing factor to
the disease mechanism of TANGO2 deficiency.1 A total of
29 cases have been reported to date (Tables S1 and S2). The
most frequent mutation in patients with European ancestry
(minor allele frequency [MAF] 0.0013) is a 34 kB deletion of
exons 3 to 9, present in 17 patients. This change was present in
one additional patient who also carried a de novo 22q11.21
deletion inherited in trans. A missense mutation (c.460G>A/
p.Gly154Arg) has a 0.0026 MAF in the Hispanic/Latino popu-
lation and was present in six of the reported patients.1,5 Other
mutations are rare and uniquely identified within single families.
Independent of the underlying mutation, all reported cases show
a remarkably similar neurological phenotype in combination
with severe recurrent metabolic crises resulting in rhabdomyoly-
sis, severe encephalopathy and life-threatening arrhythmias.
The age of onset varied from 4 months to 8 years and in most
cases neurological symptoms were present before the first criti-
cal metabolic derangement. Biochemical findings during meta-
bolic crisis included lactic acidosis, hypoglycemia, ketonuria—
similar to mitochondrial diseases. However, the presence of
rhabdomyolysis with very high creatine kinase (CK) levels with
non-specific increase of acylcarnitines and dicarboxylic acids
were hallmarks of TANGO2 deficiency.1,5
To date, very little is known about the function of the
TANGO2 protein and its role in metabolic decompensation.
However, the clinical presentation and metabolic changes
raised the possibility that mitochondrial impairment and an
increase of ER stress may be underlying pathophysiological
factors.4,5 Notably, both, the human and the mouse orthologue
of TANGO2 (NM_152906.6), T10 (NM_138583.2)3,6 have a
mitochondrial targeting sequence suggesting mitochondrial
localization.
To further elucidate the clinical presentation and patho-
physiological background of the disease, we report nine
new patients with studies on the proteomic signature of
TANGO2-deficient fibroblasts.
2 | CASE REPORTS
We report nine novel TANGO2 cases—four male and five
female patients from seven different families, summarized in
Table 1. All patients presented with a very similar clinical phe-
notype of progressive neurodevelopmental decline and recur-
rent metabolic crisis, combined with distinct biochemical
findings. Five out of seven patients showed no complications
during pregnancy, delivery or neonatal period, although two
individuals (subject 1 and subject 3.2) were small for gesta-
tional age and presented with severe microcephaly at birth
(head circumference 31 cm, sodium dodecyl sulfate (SDS) -2,
9, and 32 cm, SDS -2,8 respectively). Expanded newborn
screening for inherited metabolic diseases was normal in four
out of seven cases. The first symptoms occurred before 2 years
of age when psychomotor retardation became evident in all
patients, commonly associated with mild generalized muscular
hypotonia, difficulties or inability to ambulate and cognitive
impairment with poor or absent speech development.
All patients had metabolic encephalomyopathic crises
between 6 months (subject 1) and 9 years (subject 2.2) of
age. In the intervals the patients achieved a stable metabolic
status with nearly normalized laboratory values and a good
general condition. However, a progressive neurological
decline with severe global psychomotor retardation was pre-
sent in most patients except for subject 2.2, who only had
moderate intellectual disability with learning difficulties,
requiring special education. Most reported subjects devel-
oped epilepsy and progressive ataxia with dysarthric speech,
inability to walk and spasticity. Brain MRI was abnormal,
showing a mild global brain atrophy in two patients (sub-
jects 1 and 4) and microcephaly in subject 3.2 (Figure S1).
The metabolic crises were characterized by an acute onset,
often triggered by infection or physical stress. Serum biochem-
istry testing showed a very similar pattern in all cases with
very high (419-400 000 U/L) CK levels, lactic acidosis, ele-
vated transaminases and hyperammonemia. Hypoglycemia
was documented in two patients (subject 1 and subject 6) and
non-specific elevation of acylcarnitines and dicarboxylic acids
in four patients (subject 1, 4, 5, and 6) suggestive of general-
ized energy deficiency. Ketonuria and thyroid stimulating hor-
mone (TSH) elevation was present in 8/9 cases. TSH elevation
was treated with L-Thyroxin in subject 2.1, 2.2, 3.1, 3.2,
4, and 6. Cerebrospinal fluid analysis did not reveal signs of
metabolic derangement in any patients.
In line with the characteristic biochemical alterations
during metabolic crises, all patients showed overlapping
clinical presentations with repeated bouts of massive rhabdo-
myolysis, hepatopathy and often severe encephalopathy with
unresponsiveness and generalized seizures, requiring intensive
care unit treatment. Some of our reported patients developed
life-threatening arrhythmias (Torsade de Pointes) on the basis
of a Long-QT-Syndrome. Malignant arrhythmias led to pre-
mature death in three cases: subject 2.2 at the age of 12 years
after she had experienced several encephalomyopathic epi-
sodes, subject 3.2 at the age of 5 years without any prior meta-
bolic derangements and despite propranolol therapy and
subject 4 at the age of 8 years. Subject 2.1 survived various
arrhythmic episodes, developed left ventricular failure and
died because of a bacterial superinfection resulting in multi-
organ failure at the age of 7 years. Subject 3.1, regardless of
continuous propranolol therapy, developed repetitive life
threatening arrhythmias which he survived. Subjects 1, 4,
5, and 7 showed a long QT syndrome in ECG, and subject
4 died at the age of 8 years due to cardiac complications.
Hypertrophic cardiomyopathy was observed in subject 5.
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Autopsy of subject 2.1 and 2.2 revealed diffuse edema of
the central nervous system, myocardial softening, with dilata-
tion of cavities. The histological examination showed mild dis-
array of overall architecture of myocytes with hypertrophy and
mild interstitial fibrosis. In skeletal muscle, necrosis was pre-
sent, in line with repeated episodes of rhabdomyolysis. In liver,
hepatocyte cytoplasm appeared granular with few fat vacuoles
in subject 2.1 without abnormal glycogen storage (Figure S2).
The clinical phenotype and unique biochemical profile
were highly suggestive of a metabolic muscle disease; there-
fore, muscle biopsy has been performed in seven cases from
six different families (subject 1, 2.1, 2.2., 3.1, 4, 5, 7). Fol-
lowing the working diagnosis of an underlying metabolic
myopathy (potentially mitochondrial), anabolizing manage-
ment was performed during the acute crises leading to a
slow stabilization of the metabolic derangement in the
majority of episodes. The reported patients received supple-
mental therapy consisting of riboflavin (vitamin B2), carni-
tine and thiamine (vitamin B1) (subject 1), carnitine, vitamin
A/E/B2 (subject 2.1, 2.2), or vitamin B1 and carnitine
respectively (subject 3.1 and 3.2). This supplemental therapy
was continued in the interval but could not prevent repetitive
metabolic decompensations in subject 1, 2.1, 2.2, and 3.1.
The pharmaceutical regimen was expanded with Q10 substi-
tution for subject 1 and subject 3.1, with regard to reduced
CoQ10 levels, which helped prevent further metabolic
derangements to date. Subject 4 did not receive any specific
therapy.
3 | METHODS
3.1 | Genetic studies
Whole exome sequencing (WES) was applied in subjects
1, 3.1, 3.2, and 4. Whole genome sequencing (WGS) was per-
formed in subjects 2.1 and 2.2 (see Supplementary Materials).
In subjects 5, 6, and 7, targeted sequencing of the TANGO2
gene (NM_152906.5) was undertaken using BigDye Termi-
nator v3.1 Sanger sequencing on an ABI3130xl.
3.2 | Muscle histology and biochemistry
Muscle histology and spectrophotometric analysis of the
respiratory chain enzymes was performed as previously
described.7,8 Muscle CoQ10 analysis was done by high per-
formance liquid chromatography with electrochemical detec-
tion, as reported9
3.3 | Cell culture
Primary human fibroblasts from patients and controls were
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10% fetal bovine serum, 1% penicillin/streptomycin,
2 mM L-glutamine, 1x non-essential amino acids, 1x mini-
mum essential medium vitamins, 1 mM sodium pyruvate,
50 μg/mL uridine (ThermoFisher Scientific), at 37C, in a
humidified 5% CO2 atmosphere.
3.4 | Immunoblotting
Immunoblotting was performed as described previously.10
Primary antibodies were Anti-C22orf25 antibody (Abcam,
ab87576), GAPDH antibody (FL-335) (Santa Cruz, sc-
25778), alpha tubulin (Abcam, ab7291), Anti-VDAC1
(Abcam, ab14734). Oxidative phosphorylation (OXPHOS)
proteins were probed using Total OXPHOS Human WB
Antibody Cocktail (Abcam, ab110411) in subjects 1, 2.1
2.2, 4, 6. In Family 2 proteins were detected fluorescently
using the Total OXPHOS Antibody Cocktail and Anti-
VDAC1/Porin antibody (Abcam, ab154856) using fluores-
cently labeled secondary antibodies (Licor IRDye 800CW
anti-rabbit, 926-32211 and Licor IRDYE 680RD anti-
mouse, 925-68070) and visualized on a Licor Odyssey CLx.
3.5 | Golgi trafficking
Golgi-apparatus (GA)-ER retrograde transport was analyzed
by immunofluorescence using anti-GM130 antibody
followed by microscopy in fibroblasts of subject 2.1 and 2.2
as well as control cells. To monitor GA-ER retrograde vesi-
cle transport the number of cells with assembled GA was
counted at different time points upon Brefeldin A (BFA)
treatment, an inhibitor of the ER-Golgi anterograde trans-
port.11 For each experimental condition 100 to 125 cells
were counted. The results were expressed as percentage of
cells with assembled GA.
3.6 | Proteomic analysis
In total six samples (three TANGO2-patient derived fibro-
blasts [subjects 1, 3.1, and 4] and three control fibroblast
lines) were processed independently. Sample preparation
was performed using filter-aided sample preparation as
described previously.12 Data analysis of the acquired label
free quantitative MS was performed using the Progenesis
LC-MS software from Nonlinear Dynamics (Newcastle
upon Tyne, UK) (see Figure 2 and supplementary material).
4 | RESULTS
4.1 | Genetic studies
In subject 1 mutation analysis of several candidate genes
was negative including POLG and the known CoQ10
biosynthesis genes. WES identified a homozygous nonsense
mutation (c.262C>T, p.Arg88*) in the TANGO2
(NM_152906.5) gene (Figure S3). This variant is predicted
to result in a premature stop codon and not present in ExAc
or Bravo databases. In subject 2.1 and 2.2 focused single
gene analysis comprised NGS panel for genes associated
with channelopathies, Long QT syndrome, DMD, LPIN1,
and RYR1 were negative. WGS revealed a heterozygous
TANGO2 mutation (c.11_13delTCT, p.Phe5del) and a puta-
tive gene deletion causing a loss in the second allele, which
could not be detected by analysis of structural variation.
Subject 3 and 3.1. are homozygous carriers of the mutation
c.380+1G>A, affecting the exon 5 essential splice site
(Figure S3). In subject 4 targeted sequencing of DMD and
LPIN1 were normal and no mitochondrial deletions were
detected. After the first TANGO2 mutations had been publi-
shed, WES results were re-evaluated, detecting a novel
homozygous missense mutation in TANGO2: c.220A>C, p.
Thr74Pro (Figure S3). In subject 5, no pathogenic mutations
were detected in ACADVL, ACAD9 or LPIN1. WES initially
revealed no clear cause for these symptoms. Targeted
sequencing of the TANGO2 gene revealed a hemizygous
deletion of exons 3 to 9, proven to be inherited from her
father. The second mutation, which resulted in allele loss
could not be identified. Subject 6 underwent targeted Sanger
sequencing of the coding regions of TANGO2 revealing a
homozygous in-frame deletion c.6_9del, p.Phe6del. In Sub-
ject 7, a heterozygous mutation in VLCAD was detected but
not considered relevant as VLCAD enzyme activity was nor-
mal in the cultured fibroblasts. Targeted sequencing of the
TANGO2 gene revealed a homozygous deletion of exons
3 to 9.
4.2 | Muscle histology and biochemistry
Muscle histology and histochemistry of subjects 1, 2.1, 2.2,
3.1, and 4 revealed a mild variation of fiber diameter but no
ragged-red fibers or COX-deficient fibers. All samples
showed a variable extent of regenerative and degenerative
changes including necrosis, consistent with the history of
rhabdomyolysis. Muscle histology for subject 1 shows mild
variation of fiber diameters in the H&E staining (A) and no
signs of mitochondrial accumulation in trichrome staining
(B) (Figure S2). In subject 4, there was a significant type
2 fiber predominance, up to 80%. All samples were taken in
a symptom-free interval without acute rhabdomyolysis. In
subject 1 electron microscopic examination was performed
and did not show any relevant alterations of mitochondrial
morphology. In subject 5, muscle biopsy analysis revealed
significant lipid accumulation similar to defects of fatty acid
oxidation, which is a non-specific finding. No muscle biopsy
was taken from subject 6. The muscle biopsy from subject
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7 showed evidence of previous muscle fiber degeneration
and necrosis, likely due to repeated episodes of muscle fiber
breakdown with rhabdomyolysis. Electron microscopy
results did reveal large areas of degenerative and regenera-
tive fibers with clumping of mitochondria and some mito-
chondria appearing enlarged, with no inclusions observed
and without typical changes of primary mitochondrial
dysfunction.
OXPHOS activities were measured in several cases,
although no uniform pattern of changes was identified
across all patients (Table S3). In subject 1, biochemical
assessment of the respiratory chain enzyme activities rev-
ealed a combined decrease involving complexes I and IV,
with an associated CoQ10 deficiency (Table S3). A second
muscle biopsy taken a few years later confirmed these ear-
lier findings (results not shown). Subject 2 showed multi-
ple deficiencies in mitochondrial respiratory chain enzyme
activities in muscle, relative to an observed increased cit-
rate synthase activity while investigations in fibroblasts
were normal. CoQ10 in muscle was decreased. In subject
4 muscle respiratory chain activities were all normal,
although western blot analysis of the OXPHOS complexes
revealed a subtle reduction in important subunits of com-
plexes II, III, IV (Figure 1B). In subject 3.1 and subject
3.2 respiratory chain activity was not analyzed. Respira-
tory chain enzyme activities in subjects 5 and 7 were
normal.
4.3 | Immunoblotting
In subject 1 TANGO2 protein levels in primary fibroblasts
were markedly reduced when compared to two different
controls, although we still detected a very slight residual
band, which is unexpected in the case of a homozygous non-
sense mutation (Figure 1). In subject 2.1 we found similar
results with markedly reduced TANGO2 protein levels as
well as in subject 4 and subject 6 with an underlying mis-
sense mutation (Figure 1A).
Western blot analysis of total protein lysate from fibro-
blasts of subject 1 showed a significant decrease in steady
state levels of OXPHOS components of complex I
(P = .034812) and complex III (P = .003068) when com-
pared to two control fibroblast cell lines. Subject 4 presented
a reduction in OXPHOS complexes II, III, IV (Figure 1B).
Whereas western blot analysis from subject 2.1 and 2.2
showed a non-specific increase of all OXPHOS complexes
as a possible compensatory reaction. The defect of OXPHOS
complexes was not linked to any specific TANGO2
genotype.
4.4 | Golgi trafficking
To determine whether the functionality of the GA-ER retro-
grade vesicle transport could be affected in TANGO2 defi-
cient cells we monitored the disassembly of the GA upon
BFA treatment in subjects 2.1.and 2.2. Our results showed
FIGURE 1 A, Immunoblotting for TANGO2
protein in control fibroblasts (C) and patient
fibroblasts (P) in Families 1, 2, and 4. In Family
6, TANGO2 protein levels in muscle lysates of two
controls and two patients. Western blotting was
performed in triplicates. B, Western blot analysis
of OXPHOS complex subunits performed in total
protein lysates from primary fibroblasts in the
patients in Families 1 and 2, and in muscle lysates
from patients and controls in Family 4
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that 5 to 10 minutes after addition of BFA to the culture
medium the GA was disassembled in the 55% of the control
cells. In contrast, in TANGO2 patients the amount of cells
with disassembled GA at the same time points was reduced
to 33% (Figure 3). Although 60 minutes after BFA treatment
all cells showed disassembled GA in both control and
patient cells, the delayed disassembly detected at earlier time
points is suggestive of a possible impairment in the
FIGURE 2 Proteomic profiling of patient derived fibroblasts: A, Proteomic workflow applied to identify the proteins affected by the
TANGO2-deficiency in fibroblasts. B, Volcano-plot of proteomic findings. Red dots represent proteins showing a statistically significant decrease,
whereas green dots represent proteins with a statistically significant increase in abundance. C, Subcellular distribution of affected proteins
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retrograde GA-ER trafficking in TANGO2 patient fibro-
blasts (Figure 3).
4.5 | Proteomic signature of fibroblasts
carrying autosomal recessive TANGO2
mutations
Here, we analyzed the proteomic signature of our patients`
fibroblasts (subjects 1, 3.1, and 4) using a label-free approach
(Figure 2.13 We found that 2.3% of the quantified proteins
(55 out of 2355) were significantly differentially abundant
upon TANGO2 mutations in fibroblasts: 16 (29%) of these
proteins were increased and 39 (71%) decreased. The affected
proteins are localized in the ER-Golgi network (eg, cell
migration-inducing and hyaluronan-binding protein CEMIP,
protein transport protein Sec23B), the secretory pathway (eg,
peroxidasin homolog PXDN, serine protease HTRA1), the
plasma membrane (eg, gap junction protein alpha-1 CXA1,
major prion protein PRIO, sodium dependent phosphate
transporter 2 S20A2) and in mitochondria (eg, aldehyde
dehydrogenase 4 AL4A1) (Figure 2). In addition, significant
changes were detected in proteins involved in fatty acid oxi-
dation (eg, mitochondrial carnitine/acylcarnitine carrier pro-
tein MCAT, Fatty aldehyde dehydrogenase AL3A2) and
amino acid metabolism (eg, methylmalonate-semialdehyde
dehydrogenase MMSA). SLC25A20, encoding a mitochon-
drial carnitine/acylcarnitine carrier protein was decreased in
TANGO2-patient derived fibroblasts. For an overview on the
regulated proteins and proposed functions, see Table S4.
Interestingly, protein levels for OXPHOS complexes I, III,
IV, and V were not significantly altered in fibroblasts,
whereas complex II and TANGO2 protein were not detected
by proteomic analysis in normal and mutant fibroblasts




FIGURE 3 Golgi apparatus (GA)-to-endoplasmic reticulum (ER) retrograde membrane flow. A, Immunofluorescence using anti-GM130
antibody followed by microscopy in TANGO2 patient fibroblasts (subject 2.2) and control cells. B, To monitor GA-ER retrograde vesicle transport
the number of assembled GA at different time points upon Brefeldin (BFA) treatment (in percent) in both subjects (subject 2.1 and 2.2) and
controls. C, Mean number of assembled GA at different time points upon BFA treatment (in percent) and error. Five and 10 minutes after BFA
addition to the culture medium, a reduction of around 20% in the amount of cells with assembled GA was observed in both patients compared with
control cells
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5 | DISCUSSION
We report nine children presenting during early childhood
with severe psychomotor developmental delay, refractory
seizures and recurrent metabolic crises with lactic acidosis,
accompanied by rhabdomyolysis, cardiac arrhythmias and
encephalopathy. Next generation sequencing revealed five
novel mutations, and we show that four mutations result in a
relevant reduction or dysfunction of TANGO2 protein in
fibroblasts, suggesting a loss of function disease mechanism.
Previous studies utilizing fibroblasts derived from
patients with TANGO2 mutations suggested ER stress and
altered Golgi volume density and noted defective mitochon-
drial fatty acid oxidation.1,5 In two of our cases biochemical
investigation revealed a reduced activity of different
OXPHOS complexes in skeletal muscle (subject 1, 2.1) and
normal OXPHOS activity in subject 4 (Table S3). These
findings are underscored by Western blot analysis of
OXPHOS complex subunits showing significant reduction
of complexes I and III in subject 1 and II, III, IV in subject
4, respectively (Figure 1). Moreover, respiratory chain ana-
lyses showed CoQ10 deficiency in subject 1 and 2.1, while
in the other reported subjects CoQ10 levels were not
assessed. This CoQ10 reduction might be a secondary effect
of the fatty acid oxidation impairment, similar to CoQ10
deficiency in multiple acyl-CoA dehydrogenase defi-
ciency.14,15 We initiated a CoQ10 and riboflavin supplemen-
tation in subjects 1 and 3.1 which resulted in clinical
improvement and stabilization without any further metabolic
crisis up until now, however assessing treatment with CoQ10
and measuring CoQ10 in additional patients is needed before
our findings can be generalized.
To date a total of 29 patients have been reported with bi-
allelic TANGO2 mutations prior to this publication, all of
which show a strikingly similar clinical phenotype. How-
ever, the biochemical phenotype is more variable. Except for
an isolated mild reduction of complex I in one case1 the
majority of the reported cases showed essentially normal
mitochondrial studies2 without clear respiratory chain dys-
function (15 out of 18 cases in which mitochondrial studies
were performed, Table S1). We performed proteomic profil-
ing in fibroblasts, which indicated altered fatty acid oxida-
tion, folic acid and pyrimidine metabolism in
mitochondria.16 Impaired fatty acid oxidation was suggested
by decrease of fatty aldehyde dehydrogenases (ALDH3A2,
ALDH4A1, ALDH6A117;) and SLC25A20, encoding a
mitochondrial carnitine/acylcarnitine carrier protein.18,19
Mutations in these genes lead to severe neurological abnor-
malities, developmental delay, cardiomyopathy, arrhyth-
mias, skeletal muscle damage, liver dysfunction, and
episodes of life-threatening coma,20,21 many of these clinical
findings are also present in TANGO2-deficient patients.
Our proteomics results underline the impaired function of
the protein processing machinery (Figure 2, Table S4) as
earlier described,4 and Golgi trafficking (Figure 3). In addi-
tion, the proteomic signature of TANGO2-mutant fibroblasts
suggests an effect of the perturbed ER-Golgi system on tar-
get proteins (HTRA1, ITA1, ITA3, NCAM1, NEGR1,
NTRI, PRIO, S20A2, and SYNP2). SYNP2 modulates F-
actin networks22 and may contribute to skeletal muscle vul-
nerability and rhabdomyolysis in TANGO2 deficient
patients. SDC3 organizes cell shape through actin cytoskele-
ton and regulates adult myogenesis,23 MYLK acts as a
calcium/calmodulin-dependent myosin light chain kinase
and CAVN2 plays an important role in caveolar biogenesis
and morphology. Caveolinopathy, a muscle disease based
on mutations in Caveolin-3 can also present with muscle
pain and rhabdomyolysis,24 clinical manifestations in
TANGO2-patients. The TANGO2-related cardiac phenotype
is suggested by decrease of CXA1/CX43/GJA1.25 Thus, our
data indicate that mitochondrial and ER-Golgi function
along with proper processing of secreted and plasma mem-
brane proteins and fatty acid oxidation are predominantly
affected by loss of functional TANGO2, highlighting these
processes as relevant for TANGO2 pathophysiology and
most likely for TANGO2-dependent disease manifestation.
Taken together, proteomic signature of TANGO2-patient
derived fibroblasts suggests new clues into the underlying
pathophysiology providing a rational for future targeted ther-
apy. Avoidance of typical precipitants (catabolic stress,
especially during infection, trauma, vomiting) is rec-
ommended, although metabolic derangement did also occur
in some patients without any identifiable trigger.
Anabolizing management, treatment with vitamin B1, B2
and carnitine resulted in stabilization of metabolic crises in
the reported patients, together with consequent treatment of
organic complications (eg, hyperammonemia, seizures, car-
diac arrhythmias). Two of the reported subjects additionally
received CoQ10 and did not suffer any further metabolic
derangements to date. This highlights that in addition to the
impairment of ER-Golgi, alterations of mitochondrial fatty
acid oxidation, respiratory chain and amino acid pathways
significantly contribute to the clinical presentations of
TANGO2 deficiency.
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